Literature DB >> 12441262

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases.

J A McKay1, L J Murray, S Curran, V G Ross, C Clark, G I Murray, J Cassidy, H L McLeod.   

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) often correlates with an aggressive tumour phenotype and poor prognosis. To examine the relevance of EGFR in colorectal cancer, we determined the expression of EGFR protein in 249 colorectal adenocarcinomas and 42 lymph node metastases using immunohistochemistry. Moreover, we investigated a (CA)(n) dinucleotide repeat polymorphism of the EGFR gene in a subset of 114 tumours. High levels of EGFR protein were observed in 123/249 (49.4%) samples. EGFR expression in colorectal carcinomas correlated with differentiation grade (P=0.014). However, there were no associations with Dukes' stage, site, patient age or gender. EGFR protein expression did not influence survival in this colorectal cancer patient cohort (P>or=0.05). Expression was not identical in paired colorectal tumours and lymph node metastases, with only 17/42 (40.5%) samples showing equivalent EGFR levels (P>0.05). The distribution of the (CA)(n) dinucleotide repeat alleles in colorectal adenocarcinomas was not associated with EGFR protein expression (P>0.05). These results indicate that while EGFR overexpression is a common event in colorectal carcinogenesis, it does not influence patient prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441262     DOI: 10.1016/s0959-8049(02)00234-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  59 in total

1.  HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Authors:  David Liska; Chin-Tung Chen; Thomas Bachleitner-Hofmann; James G Christensen; Martin R Weiser
Journal:  Clin Cancer Res       Date:  2010-11-22       Impact factor: 12.531

2.  FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.

Authors:  Alexandros Garouniatis; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

3.  Identify lymphatic metastasis-associated genes in mouse hepatocarcinoma cell lines using gene chip.

Authors:  Bo Song; Jian-Wu Tang; Bo Wang; Xiao-Nan Cui; Li Hou; Lu Sun; Li-Min Mao; Chun-Hui Zhou; Yue Du; Li-Hui Wang; Hua-Xin Wang; Ren-Shu Zheng; Lei Sun
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

4.  Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation.

Authors:  Guofeng Xie; Zhongsheng Peng; Jean-Pierre Raufman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-23       Impact factor: 4.052

Review 5.  Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.

Authors:  Jeanne Tie; Jayesh Desai
Journal:  Target Oncol       Date:  2014-08-15       Impact factor: 4.493

Review 6.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.

Authors:  Rafal Wierzbicki; Derek J Jonker; Malcolm J Moore; Scott R Berry; Patrick J Loehrer; Hagop Youssoufian; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2009-10-15       Impact factor: 3.850

8.  Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers.

Authors:  Marie-Pierre Buisine; Agnes Wacrenier; Christophe Mariette; Emmanuelle Leteurtre; Fabienne Escande; Sana Aissi; Amandine Ketele; Annette Leclercq; Nicole Porchet; Thecla Lesuffleur
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

9.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

Authors:  R L Rego; N R Foster; T C Smyrk; M Le; M J O'Connell; D J Sargent; H Windschitl; F A Sinicrope
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

10.  Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Authors:  M J Overman; J Pozadzides; S Kopetz; S Wen; J L Abbruzzese; R A Wolff; H Wang
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.